Can bone scans guide therapy with radium-223 dichloride for prostate cancer bone metastases?

BACKGROUND: Radium-223 dichloride (Ra-223 Xofigo) has recently been approved as an addition to the host of available therapies in the USA as a treatment option for metastatic castrate-resistant prostate cancer (mCRPC) with bone metastases. This study describes our initial experience in patients trea...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Manag Res
Egile Nagusiak: Gayed, Isis, Salama, Vivian, Dawood, Lydia, Canfield, Steven, Wan, David, Cai, Chunyan, Joseph, Usha, Amato, Robert
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove Medical Press 2018
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6135075/
https://ncbi.nlm.nih.gov/pubmed/30233247
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S166218
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak